plecanatide

Cantor Fitzgerald initiated coverage of Synergy Pharmaceuticals Inc (NASDAQ: SGYP) at Overweight with a price target of $11. Analyst William Tanner estimates second quarter earnings of $1.4 million with a negative $0.25 EPS. Fiscal 2017 earnings are estimated to be $11.3 million. Opportunities In...

Synergy Pharmaceuticals Inc (NASDAQ: SGYP) presented positive results from its Phase 3 study of plecanatide for the treatment of irritable bowel syndrome with constipation (IBS-C). In two large studies, Synergy examined plecanatide, marketed as "Trulance," in both 3 mg and 6 mg doses....

Synergy Pharmaceuticals Inc (NASDAQ: SGYP) announced last week it has been issued three new patents from the U.S. Patent and Trademark Office. The first patent relates to the manufacturing method for TRULANCE (plecanatide) and the other two relate to formulations and methods of using Trulance for...

Biotech stocks are regaining some lost momentum after Wednesday's Trump-inspired selloff that took a toll on the sentiment on pharma sector. The weakness was so stark that it made CNBC's Brian Sullivan tweet that biotechs/healthcare was the only sector to have been left out of what seemed...

Biopharma companies did not have much to write home about in the year 2016, as negative news flow on price gouging hit many stocks in the space. The SPDR S&P Biotech (ETF) (NYSE: XBI) and the iShares NASDAQ Biotechnology Index (ETF) (NASDAQ: IBB) are down 13.93 percent and 20.36 percent,...

Rodman & Renshaw’s Raghuram Selvaraju believes the top-line data announced by Synergy Pharmaceuticals Inc (NASDAQ: SGYP) from the first pivotal trial for plecanatide in constipation-predominant irritable bowel syndrome (IBS-C) positions the pipeline candidate as a “potentially best-...

Synergy Pharmaceuticals Inc (NASDAQ: SGYP) announced after Thursday's closing bell that its drug plecanatide, a daily pill to fight irritable bowel syndrome, had achieved positive top-line results from the second of two pivotal phase 3 clinical trials evaluating the efficacy and safety of the...

Last Friday, shares of Synergy Pharmaceuticals Inc (NASDAQ: SGYP) traded down 5.78 percent, even though the company made public positive data from its first of two Phase III trials for its clinical constipation-predominant irritable bowel syndrome (IBS-C) drug, plecanatide. On Monday, research...

Before Friday's market open, Synergy Pharmaceuticals Inc (NASDAQ: SGYP) announced positive data from its first of two Phase 3 trials for clinical constipation-predominant irritable bowel syndrome (IBS-C) drug plecanatide. “We are very pleased with these results,” said Gary S. Jacob,...